H5N1 Infection (Avian Influenza) - Pipeline Review, H2

2015 Is Released
H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015 Summary Global Markets Direct s, H5N1
Infection (Avian Influenza) - Pipeline Review, H2 2015, provides an overview of the H5N1 Infection
(Avian Influenza)s therapeutic pipeline. This report provides comprehensive information on the
therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at
various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and featured news and press
releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian
Influenza) and special features on late-stage and discontinued projects. Global Markets Directs report
features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced from Global Markets Directs
proprietary databases, Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report
reviews key pipeline products under drug profile section which includes, product description, MoA and
R&D brief, licensing and collaboration details & other developmental activities - The report reviews key
players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all
their major and minor projects - The report summarizes all the dormant and discontinued pipeline
projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies
and universities/research institutes based on information derived from company and industry-specific
sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and
combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the
basis of target, MoA, route of administration and molecule type - Latest news and deals relating related
to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies - Identify emerging players with
potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for H5N1
Infection (Avian Influenza) - Plan mergers and acquisitions effectively by identifying key players of the
most promising pipeline - Devise corrective measures for pipeline projects by understanding H5N1
Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive
1

projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by
identifying discontinued projects and understanding the factors that drove them from pipeline.
with TOC
@ http://www.idatainsights.com/reports-landing-page.php?id=173366/h5n1infection-avian-influenza-pipeline-review-h2-2015

Browse

To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173366/h5n1-infection-avian-influenza-pipeline-review-h2-2015

Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
H5N1 Infection (Avian Influenza) Overview 10
Therapeutics Development 11
Pipeline Products for H5N1 Infection (Avian Influenza) - Overview 11
Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis 12
H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 13
H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 18
H5N1 Infection (Avian Influenza) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
H5N1 Infection (Avian Influenza) - Products under Development by Companies 22
H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 27
H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 28
Akshaya Bio Inc. 28
Altimmune, Inc. 29
Antigen Express, Inc. 30
Aphios Corporation 31
Aprogen, Inc. 32
BioDiem Ltd 33
2

BiondVax Pharmaceuticals Ltd. 34

CEL-SCI Corporation 35
Cocrystal Pharma, Inc. 36
CSL Limited 37
Daiichi Sankyo Company, Limited 38
Emergent BioSolutions Inc. 39
Gemmus Pharma Inc. 40
GlaxoSmithKline Plc 41
Green Cross Corporation 42
Hemispherx Biopharma, Inc. 43
iBio, Inc. 44
Immunovaccine, Inc. 45
Inovio Pharmaceuticals, Inc. 46
Johnson & Johnson 47
Kineta, Inc. 48
Medicago Inc. 49
MedImmune, LLC 50
Microbiotix, Inc. 51
Microgen Scientific Industrial Company for Immunobiological Medicines 52
Myelo Therapeutics GmbH 53
NanoBio Corporation 54
Nanotherapeutics, Inc. 55
NanoViricides, Inc. 56
NewLink Genetics Corporation 57
OPKO Health, Inc. 58
PaxVax, Inc. 59

PDS Biotechnology Corporation 60

PeptiDream Inc. 61
Protein Sciences Corporation 62
Shionogi & Co., Ltd. 63
Sirnaomics, Inc. 64
Takeda Pharmaceutical Company Limited 65
TechnoVax, Inc. 66
Theraclone Sciences, Inc. 67
Vaxine Pty Ltd 68
VaxInnate Corporation 69
H5N1 Infection (Avian Influenza) - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 74
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
A-06 - Drug Profile 80
AE-443p - Drug Profile 81
Alferon LDO - Drug Profile 83
AP-302 - Drug Profile 84
APP-0205 - Drug Profile 85
APP-309 - Drug Profile 86
AT-301 - Drug Profile 87
CEL-1000 - Drug Profile 88
DP-C005 - Drug Profile 90
4

FBF-001 - Drug Profile 91

FDX-000 - Drug Profile 92
Gamma-Flu - Drug Profile 93
GP-1001 - Drug Profile 94
GP-1002 - Drug Profile 95
GP-1681 - Drug Profile 96
GREFLU/VIE - Drug Profile 98
HAI-05 - Drug Profile 99
iHA-24 - Drug Profile 100
Influ-nRNA - Drug Profile 101
influenza (strain H5N1, H1N1) vaccine - Drug Profile 102
influenza [strain A/H5N1] vaccine - Drug Profile 103
influenza [strain A/H5N1] vaccine - Drug Profile 104
influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine - Drug Profile 105
influenza [strain H5N1] (split virion) vaccine - Drug Profile 106
influenza [strain H5N1] vaccine - Drug Profile 107
influenza [strain H5N1] vaccine - Drug Profile 108
influenza [strain H5N1] vaccine - Drug Profile 109
influenza [strain H5N1] vaccine - Drug Profile 110
influenza [strain H5N1] vaccine - Drug Profile 112
influenza [strain H5N1] vaccine - Drug Profile 113
influenza [strain H5N1] vaccine - Drug Profile 114
influenza [strain H5N1] vaccine - Drug Profile 115
influenza [strain H5N1] vaccine - Drug Profile 116
influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 117
influenza [strain H5N1] virus like particles vaccine - Drug Profile 119

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 121

influenza A vaccine - Drug Profile 122
influenza vaccine - Drug Profile 123
influenza vaccine - Drug Profile 124
influenza virus like particle vaccine - Drug Profile 126
Innate Immune Adjuvants - Drug Profile 127
INO-3510 - Drug Profile 128
IPS-07 series - Drug Profile 129
JNJ-872 - Drug Profile 130
KD-295 - Drug Profile 132
KIB-PCI - Drug Profile 133
M-001 - Drug Profile 134
MBX-2329 - Drug Profile 137
MBX-2546 - Drug Profile 139
MEDI-550 - Drug Profile 140
MG-1109 - Drug Profile 142
Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile 144
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 145
MVAH-5HA - Drug Profile 146
Myelo-001 - Drug Profile 147
NVINF-1 - Drug Profile 148
NVINF-2 - Drug Profile 150
OrniFlu - Drug Profile 151
PanBlok - Drug Profile 152
PDS-0102 - Drug Profile 154
PNSIA-28 - Drug Profile 155
PNSIA-49 - Drug Profile 156
6

PXVX-0103 - Drug Profile 157

rintatolimod - Drug Profile 159
S-033188 - Drug Profile 161
Small Molecules to Activate Sirtuin for Influenza - Drug Profile 162
Small Molecules to Inhibit Endonuclease for Flu - Drug Profile 163
STP-702 - Drug Profile 164
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 165
TCN-032 - Drug Profile 166
TVX-003 - Drug Profile 168
VAX-161 - Drug Profile 169
VGX-3400X - Drug Profile 170
VH-244 - Drug Profile 172
H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 174
H5N1 Infection (Avian Influenza) - Dormant Projects 200
H5N1 Infection (Avian Influenza) - Discontinued Products 205
H5N1 Infection (Avian Influenza) - Product Development Milestones 206
Featured News & Press Releases 206
Appendix 213
Methodology 213
Coverage 213
Secondary Research 213
Primary Research 213
Expert Panel Validation 213
Contact Us 213
Disclaimer 214"

Read More
http://www.idatainsights.com/reports-landing-page.php?id=173366/h5n1-infectionavian-influenza-pipeline-review-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
ContactUs:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects